Zhao Laboratory
Di Zhao, Ph.D.
Principal Investigator
Areas of Research
- Prostate Cancer
- Targeted Therapy
Dr. Zhao’s laboratory in the Experimental Radiation Oncology (ERO) department is interested in the functional genomics of prostate cancers with two primary directives: (1) understanding how oncogenic signaling pathways and tumor microenvironment regulate cancer development and metastasis, and (2) searching for biomarkers and context-specific therapeutic targets for personalized cancer medicine.
Recent Publications
Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, Chen F, Zhang J, Mak DH, Van V, Leo J, St Croix B, Aparicio A, Zhao D. Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies. Sci Transl Med 15(695):eadf6724, 5/2023. e-Pub 5/2023. PMID: 37163614.
Li H, Gigi L, Zhao D. CHD1, a multifaceted epigenetic remodeler in prostate cancer. Frontiers in Oncology. 13. doi: 10.3389/fonc.2023.1123362, 1/2023. e-Pub 1/2023. PMID: 36776288.
Our Funding
CPRIT Recruitment of First-Time Tenure-Track Faculty Award
Explore Novel Therapeutic Targets for Advanced Prostate Cancer Harboring PTEN loss
6/1/2019-5/31/2024
Principal Investigator
NIH/NCI - 1R01CA275990-01
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
1/1/2023-12/31/2027
Principal Investigator
Prostate Cancer Foundation Challenge Award
Targeting B7-H3 in Aggressive Variant Prostate Cancer
1/25/2023-1/24/2025
Principal Investigator
The University of Texas MD Anderson Cancer Center Faculty Scholar Award
Novel Oncogenic Substrate of SPOP Reveals Therapeutic Vulnerability in Metastatic Cancers
7/10/2023-6/30/2025
Principal Investigator
Contact Information
Lab location:
Zayed Building Z7.4018
6565 MD Anderson Blvd Unit 1052
Houston, TX 77030
Contact Dr. Zhao:
P: 713-792-7328 | Office: Z7.3028
Email: Dzhao2@mdanderson.org